James Lab

Findings by Drs. Richard James and David Rawlings reveal B cell receptor signaling’s role in post-transplant lymphoproliferative disorder.

New findings from the James Lab, published in the journal Molecular Therapy, show proof-of-concept that engineered human plasma B cells can be used to treat leukemia in a humanized model, with implications for other cancers, as well as autoimmune and protein deficiency disorders.

Key findings from the Center for Immunity and Immunotherapies will be shared at the American Society of Gene and Cell Therapy’s Annual Meeting from May 7 to 11 in Baltimore, Maryland.

Located at Stewart Street and Terry Avenue in the heart of South Lake Union.

Lead author Rene Cheng and colleagues used hydrogel nanovials to link how much protein an individual B cell is secreting with that cell’s specific genetic information.

Key findings from the Center for Immunity and Immunotherapies highlighted at the American Society of Gene and Cell Therapy’s Annual Meeting from May 16 to 20 in Los Angeles.

New findings from the James Lab show engineered human antibody-secreting B cells can survive for greater than a year in a living model, which could pave the way for a new and longer-lasting delivery method for protein therapies.

We are excited to have Aaron Ramonett join the lab.

We are excited to have Greg Asher join the lab.

We are excited to have Anna Helmers join the lab.

We are excited to have Sam Dawson join the lab.

We are excited to have Ameena Romani and Parnal Nevekar join the lab. They will be working on engineering and delivery biologics to B cells.

David Rawlings and Rich James start collaboration with Be Biopharma to develop B cell therapies for protein delivery. David and Rich discuss this new therapy in the link above.

We are excited to have Rupa Devi Soligalla and Naomi Sibayan join the lab. They will be both be developing methods to engraft murine antibody secreting cells into normal immune competent hosts.

We are excited to have Andee join us after completing her undergraduate degree at the UW. She will work with the B cell engineering group to improve engineering of loci for expression of proteins by B cells.

We are excited to have Tyler Hill join the lab as a graduate student from the UW MCB program. Tyler plans to focus his studies on engineering human B cells to secrete potentially therapeutic affinity reagents.